Infectious Disease
Chikungunya Virus
1
Pipeline Programs↗
3
Active Trials↗
1
Companies Involved↗
Chikungunya Virus is an early-stage landscape with 1 program across 1 company. The most active players are Eli Lilly. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31
Approved
No programs
Analysis
Trial Status
10
clinical trials
Completed7 · 70%
Active, not recruiting1 · 10%
Not yet recruiting1 · 10%
Recruiting1 · 10%
Clinical Trials
Trial Activity
10 trials
A Phase 3b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine for the Prevention of Chikungunya Disease in Adolescents (12 to <18 Years) and Adults (≥18 Years)
Recruiting·—·Phase 3·NCT07467707·6,144 enrolled
Chikungunya Virus Vaccine Trial in Healthy Adults
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01489358·25 enrolled
Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)
Completed·—·Phase 2·NCT03992872·60 enrolled
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
Completed·—·Phase 2·NCT05065983·25 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)